COVID-19

The antiviral combination nirmatrelvir-ritonavir (Paxlovid) used for early symptoms of COVID-19 offers limited protection against the development of Long COVID.

Despite its aim to reduce in-person visits, a virtual urgent care (VUC) program in Ontario, Canada found that patients seen by a VUC provider with no further referral were more likely to visit the emergency room than those who came directly to the department.

The FDA is advising health care professionals who administer the vaccine to make sure the correct volume of the vaccine is withdrawn from the vial and the correct dose is administered to the patient.

Although long COVID has emerged as a major public health concern, it has not yet been clearly identified as a clinical condition.

A poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition, featured a complex pediatric case involving SARS-CoV-2, bacterial coinfection, multiorgan failure, thrombotic microangiopathy, and systemic hyperinflammation.

The combination vaccine produced robust immune responses from vaccine candidates in a phase 1/2 clinical trial.

Patients who were bedridden for 7 days or longer had the highest prevalence of symptoms, which included fatigue, shortness of breath, chest pain, dizziness, and trouble sleeping.

Infants of vaccinated mothers had a lower risk of severe neonatal morbidity, neonatal death, and admission to neonatal intensive care units, according to a new study published in JAMA Pediatrics.

A review published in General Hospital Psychiatry shows large, negative impacts on menopausal women.

Research findings may support further COVID-19 vaccination in children.

A study presented at IDWeek 2023 showed significantly more patients in the treatment group were alive and oxygen-free by day 29 and day 60 compared to those in the placebo group.

Moderna plans to begin a phase 3 trial of the combination vaccine this year.

The monovalent vaccine offers a protein-based non-mRNA option.

Vaccines were tested against various strains of the SARS-CoV-2 virus.

Katalin Karikó, PhD, and Drew Weissman, MD, PhD, were cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."

A new study from Yale School of Medicine and Icahn School of Medicine at Mount Sinai found that patients with long COVID had increased antibodies that help fight different viruses and lower levels of cortisol.

The presence of 4 or more comorbidities was strongly associated with a higher risk of critical outcomes, regardless of vaccination status.

A study indicates that possible disruptions in skin cancer screenings and general dermatologic care at the time of the pandemic could have resulted in fewer diagnoses of melanoma generally.

Bivalent COVID-19 vaccines by both Moderna and Pfizer-BioNTech are no longer authorized for use in the United States.

A new study found that 1 in 8 older adults with cancer and no history of depression developed the condition for the first time during the COVID-19 pandemic.

Previous clinical data has shown that the vaccine also generates a strong response to the EG.5 and FL.1.5.1 variants.

Study authors conclude that all children should be up to date with recommended COVID-19 vaccines and initiate the vaccination process immediately when products become available.

The CDC and WHO are currently tracking several variants that are driving the majority of new cases around the world.

A study published in the Lancet found that patients who had previously tested positive for COVID-19 had lower cognitive accuracy compared to negative controls.

A 510(k) clearance, or a Premarket Notification, requires device manufacturers to notify the FDA at least 90 days ahead of registration with their intent to market a medical device.

Although wastewater data and COVID case/hospitalization rates no longer accurately reflect each other, researchers suggest wastewater surveillance may be the best metric for monitoring the amount of circulating virus.

Moderna’s mRNA-1273 vaccine was associated with a lower risk of diagnosed COVID-19 when compared to Pfizer’s BNT162b2.

A study from Bavaria, Germany, found the frequency was higher among boys and children younger than the median age of 6.5 years during the pandemic.

Children who tested positive were more likely to report long COVID symptoms at 90 days than children who tested negative.

The report references adult vaccines, in terms of volume of use, for influenza, diphtheria and tetanus (Td), diphtheria, tetanus and pertussis (TDaP), hepatitis B, herpes zoster and pneumococcal.